GlassScriptPhysician profile
Ariel D Teitel
NPI 1871578450
$45,039.82
in general payments reported to CMS, 2019-2025
40 companies · $5,119 in 2025
The $5,119 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,613 · 2020: $5,550 · 2021: $5,509 · 2022: $8,307 · 2023: $7,718 · 2024: $6,223 · 2025: $5,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,665 · Consulting Fee: $1,850 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,455.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,665.00 |
| Consulting Fee | $1,850.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23,142.55 | 2019-2025 | Otezla, Enbrel, Krystexxa |
| Abbvie INC. | $6,878.77 | 2019-2025 | Rinvoq, Skyrizi |
| Celgene Corporation | $3,095.34 | 2019 | |
| Sobi, INC | $1,813.24 | 2025 | |
| Horizon Therapeutics Plc | $1,087.14 | 2019-2023 | Krystexxa |
| Ucb, INC. | $1,077.61 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,072.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $956.17 | 2021-2025 | Saphnelo, Fasenra |
| Glaxosmithkline, LLC. | $906.71 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $866.02 | 2019-2025 | Taltz |
| Janssen Biotech, INC. | $666.33 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $482.41 | 2020-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $441.37 | 2019 | |
| Janssen Scientific Affairs, LLC | $385.65 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $242.65 | 2019-2025 | Orencia |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Teitel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.